by David Cassak
For nearly a decade, one of the hottest topics in medical devices has been drug/device convergence: combining in a single...
Modeled after advanced computers used in industrial applications, such as automotives, Proteus Biomedical hopes to bring what it calls pervasive computing to treat chronic conditions such as chronic heart failure and, later on, others. The company's approach combines device and drug therapy in an innovative kind of combination products; in the process, says Proteus, it will define not just a new category of medical products but also shape a new competitive landscape.
by David Cassak
For nearly a decade, one of the hottest topics in medical devices has been drug/device convergence: combining in a single...
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
To make your document look professionally produced, Word provides header, footer, cover page, and text box designs that complement each other. For example, you can add a matching cover page, header, and sidebar. Click Insert and then choose the elements you want from the different galleries.
To make your document look professionally produced, Word provides header, footer, cover page, and text box designs that complement each other. For example, you can add a matching cover page, header, and sidebar. Click Insert and then choose the elements you want from the different galleries.
As the planet heats up and sea levels rise, the need to reduce carbon emissions is becoming ever more urgent. The life sciences industry is just one of many that are looking to cut the carbon it produces.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.